SRNE

Sorrento Therape

SRNE, USA

Sorrento Therapeutics, Inc., a clinical and commercial stage biopharmaceutical company, develops a portfolio of next-generation treatments for three therapeutic areas: cancer, infectious disease,and pain. It operates through two segments, Sorrento Therapeutics and Scilex. The company provides cancer therapeutic by leveraging its proprietary G-MAB antibody library and targeted delivery modalities, which include chimeric antigen receptor T-cell therapy (CAR-T), dimeric antigen receptor T-cell therapy, and antibody drug conjugate, as well as bispecific antibody approach; and Sofusa, a drug delivery technology that deliver biologic directly into the lymphatic system. Its clinical programs in development include anti-CD38 CAR-T therapy for the treatment of multiple myeloma, as well as for amyloidosis and graft versus host disease. The company develops resiniferatoxin, a non-opioid-based TRPV1 agonist neurotoxin for late stage cancer and osteoarthritis pain treatment; and ZTlido, a lidocaine topical system for the treatment of post-herpetic neuralgia. It engages in the development of SEMDEXA, an injectable viscous gel formulation, which is Phase III trial for the treatment of sciatica, a pathology of low back pain; SP-103, an investigational non-aqueous lidocaine topical system undergoing clinical development in chronic low back pain condition; and SP-104, a novel low-dose delayed-release naltrexone hydrochloride formulation for the treatment of fibromyalgia. It has collaboration with SmartPharm Therapeutics Inc. to develop gene-encoded antibody vaccine to protect against COVID-19; and Mayo Clinic for Phase Ib pilot study using sofusa lymphatic drug delivery technology to deliver Ipilimumab in patient with melanoma. The company was founded in 2006 and is based in San Diego, California. On February 13, 2023, Sorrento Therapeutics, Inc., along with its affiliate, filed a voluntary petition for reorganization under Chapter 11 in the U.S. Bankruptcy Court for the Southern District of Texas. The plan was later approved as C

https://www.sorrentotherapeutics.com

Stock Price

$ 0.00

0% decrease compared to yesterday.

Dividend

Frequency:

N/A

Rate:

N/A

Next Payout:

N/A
SRNE
stock
SRNE

Head to Head Survey: Sorrento Therapeutics (NASDAQ:SRNE) and ZIVO Bioscience (NASDAQ:ZIVO) Defense World

Read more →
SRNE
stock
SRNE

Contrasting Sorrento Therapeutics (NASDAQ:SRNE) & Alpha Cognition (OTC:ACOGF) Defense World

Read more →

Showing 2 of 10

Analyst Ratings & Sentiment

(Last Updated 2023-06-30)

Rating:

STRONG BUY

Target Price:

$13

Analyst Picks

Strong Buy

1

Buy

1

Hold

0

Sell

0

Strong Sell

0

Finn Analysis

(Last Updated 2023-06-30)

Health Score

Price to Book Ratio (P/B)

-

Very Low

-0.01

Low ≤ 1

High ≥ 3

Return on Equity (ROE)

-

Very High

46.42 %

Low ≤ 5%

High ≥ 25%

Return on Assets (ROA)

-

Very Low

-20.85 %

Low ≤ 2%

High ≥ 10%

Free Cash Flow - Revenue % (FCF)

-

Very Low

-371.37 %

Low ≤ 5%

High ≥ 15%

Investors

* Institutions hold a combined 0.05% of the total shares of Sorrento Therape

2.

Lattice Capital Management LLC

(0.0094%)

since

2024/06/30

3.

AVIP BlackRock Advtg Small Cp Gr Prtfl

(0.0082%)

since

2024/06/30

4.

Kitzinger Lautmann Capital Mgmt Inc

(0.0054%)

since

2024/06/30

5.

SlateStone Wealth, LLC

(0.0039%)

since

2024/06/30

6.

BNYM Mellon SL Market Completion UC1

(0.0038%)

since

2024/09/30

7.

Huntington National Bank

(0.0009%)

since

2024/06/30

8.

Guggenheim Active Allocation Fund

(0.0006%)

since

2024/05/31

9.

AlphaMark Advisors, LLC

(0.0004%)

since

2024/06/30

10.

BNYM Mellon AFLCIO SL Brd Mkt Index Inst

(0.0003%)

since

2024/09/30

11.

BNYM Mellon NSL Smid Cap Stck Index Inst

(0.0003%)

since

2024/09/30

12.

BNYM Mellon DB NSL Small Cap Stock Index

(0.0003%)

since

2024/09/30

13.

ZWJ Equity

(0.0001%)

since

2024/06/30

14.

BNYM Mellon NSL Mkt Completion Fund Inst

(0.0001%)

since

2024/09/30

15.

ARGI Investment Services, LLC

(0%)

since

2024/06/30

* Investors data is estimated based on stocks listed on Finnton that are currently held by Institution/Fund.

Earnings History

EPS ActualEPS EstimateEPS DifferenceSurprise Percent

Upcoming Earnings Release

Date

—

EPS Estimate

—

Latest Release

Date

2025-09-30

EPS Actual

0

EPS Estimate

0

EPS Difference

0

Surprise Percent

null%

Investing Fit Scorecard

(Last Updated 2023-06-30)

Deep Value
Weak Deep Value(2)
Defensive
Highly Defensive(7)
Dividend
Weak Dividend Profile(1.5)
Economic Moat
Some Competitive Advantage(5.8)
GARP
Not Attractive for GARP(2.5)
Growth
Weak Growth Prospect(2.5)
Momentum
Moderate Momentum(4)
Net Net
Not Undervalued (Net-Net)(2)
Quality
Low Quality Business(2.5)
Value
Overpriced(2.5)

Income Statement

(Last Updated 2023-06-30)

Revenue

$ 0

Cost Of Revenue

$ 0

Gross Profit

$ 0

Operating Expenses

$ 0

Operating Income

$ 0

Interest Expense

$ 0

Pretax Income

$ 0

Net Income

$ 0

Income Tax Expense

$ 0

EBITDA

$ 0

Total Other Income Expense Net

$ 0

Earnings Per Share

0

Dividends Per Share

0

Shares Outstanding

0

Operating Margin

0%

Trend

Balance Sheet

(Last Updated 2023-06-30)

Cash

$ 0

Short Term Investments

$ 0

Receivables

$ 0

Inventories

$ 0

Total Current Assets

$ 0

Property Plant Equipment

$ 0

Total Assets

$ 0

Payables

$ 0

Short Term Debt

$ 0

Long Term Debt

$ 0

Total Liabilities

$ 0

Equity

$ 0

Trend

Cash Flow

(Last Updated 2023-06-30)

Net Income

$ 0

Depreciation

$ 0

Change In Working Capital

$ 0

Cash From Operations

$ 0

Capital Expenditures

$ 0

Cash From Investing

$ 0

Cash From Financing

$ 0

Net Change In Cash

$ 0

Trend

Disclaimer: Finnton is a stock screener tool provided for informational and educational purposes only. The data, analysis, and insights offered on this website do not constitute financial, investment, tax, or legal advice. Users are solely responsible for their own investment decisions, and Finnton makes no guarantees regarding the accuracy, completeness, or reliability of the information provided. Past performance is not indicative of future results. Always conduct your own research and consult with a licensed financial advisor before making any investment decisions.